Response to Vermorken et al ‐ curcumin and free light chains

Golombick, Terry; Diamond, Terrence; Manoharan, A.; Ramakrishna, Raj

doi:10.1002/ajh.23294

Cited by 4 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussion/conclusionmentioning

confidence: 99%

“…Previous studies carried out in our clinics have demonstrated that oral administration of curcumin, even at high doses (up to 8 g daily), is well tolerated and can decrease the paraprotein load, free light chains, bone turnover, and % plasma cell dyscrasia in a selected group of patients with multiple myeloma precursor disease that is monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). [20][21][22][23] The multitude of published studies, including an in vitro study carried out in our laboratory, 16 suggest that curcumin can potentiate not only the cytotoxic effect of multiple agents used in the treatment of MM, but also enhance the chemo-sensitizing effects of these agents. The implications arising from these observations may be of important clinical benefit: i) curcumin studies can be designed to assess the additive antimyeloma effects of curcumin to the current treatment protocols and ii) curcumin may be used as an alternative to corticosteroids in such protocols.…”

Section: Discussion/conclusionmentioning

confidence: 99%

See 1 more Smart Citation

Use of Curcumin in Multiple Myeloma patients intolerant of steroid therapy

Ramakrishna

Diamond

Alexander

et al. 2020

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Section: Discussion/conclusionmentioning

confidence: 99%

Section: Discussion/conclusionmentioning

confidence: 99%

Use of Curcumin in Multiple Myeloma patients intolerant of steroid therapy

Ramakrishna

Diamond

Alexander

et al. 2020

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“… Effects of CUR on cancerous processes observed on clinical trials [ 28 – 38 ]. Carcinoembryonic antigen (CEA); vascular endothelial growth factor (VEGF); cancer antigen 15.3 (CA15.3); DNA adduct 3-(2-deoxy-β-di- erythro -pentafuranosyl)pyrimido[1,2-α]purin-10(3H)-one (M1G); enzyme cyclooxygenase-2 (COX-2); colorectal aberrant crypt foci (ACF); prostaglandin E2 (PGE2); 5-hydroxyeicosatetraenoic acid (5-HETE); phosphorylated signal transducer and activator of transcription 3 (pSTAT3); monoclonal gammopathy of undetermined significance (MGUS); nuclear factor kappa B (NF-κB).…”

Section: Reviewmentioning

confidence: 99%

Use of nanosystems to improve the anticancer effects of curcumin

Araya-Sibaja¹,

Salazar‐López²,

Wilhelm-Romero³

et al. 2021

Beilstein J. Nanotechnol.

View full text Add to dashboard Cite

Curcumin (CUR) is a phenolic compound that is safe for human consumption. It exhibits chemopreventive, antiproliferative, antiangiogenic, and antimetastatic effects. However, these benefits can be hampered due to the lipophilic nature, rapid metabolism, low bioavailability, and fast elimination of the molecule. Considering this, the present work reviews the use of CUR-based nanosystems as anticancer agents, including conventional nanosystems (i.e., liposomes, nanoemulsions, nanocrystals, nanosuspensions, polymeric nanoparticles) and nanosystems that respond to external stimuli (i.e., magnetic nanoparticles and photodynamic therapy). Previous studies showed that the effects of CUR were improved when loaded into nanosystems as compared to the free compound, as well as synergist effects when it is co-administrated alongside with other molecules. In order to maximize the beneficial health effects of CUR, critical factors need to be strictly controlled, such as particle size, morphology, and interaction between the encapsulating material and CUR. In addition, there is an area of study to be explored in the development of CUR-based smart materials for nanomedical applications. Imaging-guided drug delivery of CUR-based nanosystems may also directly target specific cells, thereby increasing the therapeutic and chemopreventive efficacy of this versatile compound.

show abstract

“…Recent clinical studies have demonstrated that oral administration of curcumin, even at high doses, is well tolerated and can decrease the paraprotein load, free light chains, bone turnover and % plasma cell infiltrate into the bone marrow in some patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) [12][13][14][15] .…”

mentioning

confidence: 99%

Curcumin enhances the cytotoxic and chemo-sensitising effects of lenalidomide in human multiple myeloma cells

Wong¹,

Golombick

Diamond³

et al. 2013

J Hemat Malig

View full text Add to dashboard Cite

Background: Curcumin, the active component of the Curcuma longa plant, has been shown to potentiate the effect of the immunomodulatory drugs (IMiDs) thalidomide and Bortezomib against human myeloma cell lines and a nude mice model. Its effect on the other IMid, lenalidomide, has not been evaluated. This study aims to investigate the mechanism of action of curcumin and its potential ability to positively interact with lenalidomide.Method: we designed an in-vitro study to investigate the cytotoxic and chemo-sensitising effects of curcumin alone and in combination with lenalidomide on the human myeloma H929 cell line. Results:Incubation of H929 cells with curcumin (30M) or lenalidomide (2.5 mM) for 3 days resulted in 26.35% (±1.06) and 30.81%(±2.98) apoptotic cells respectively. When 30 M curcumin was combined with 2.5 mM lenalidomide, 50.4% (±3.37) apoptotic cells were detected by flow cytometry and the increase was significant compared to either curcumin alone or lenalidomide alone (anova p = 0.0026). Furthermore, gene analysis studies show that curcumin enhances the cytotoxic effect of lenalidomide via suppression of the cereblon and multi-drug resistant genes. Conclusion:Curcumin exerts a cytotoxic effect additive to that of lenalidomide on H929 myeloma cells, and it also enhances the chemo-sensitizing effects of this agent.

show abstract

Response to Vermorken et al ‐ curcumin and free light chains

Cited by 4 publications

References 3 publications

Use of Curcumin in Multiple Myeloma patients intolerant of steroid therapy

Use of Curcumin in Multiple Myeloma patients intolerant of steroid therapy

Use of nanosystems to improve the anticancer effects of curcumin

Curcumin enhances the cytotoxic and chemo-sensitising effects of lenalidomide in human multiple myeloma cells

Contact Info

Product

Resources

About